BAT1308

BAT1308 is a recombinant humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor. By binding to PD-1, it inhibits its interaction with ligands and downstream signaling pathways, thereby restoring immune function through activation of T cells and promoting T-cell-mediated immune responses against tumor cells. Developed by Bio-Thera Solutions, BAT1308 is being investigated primarily for the treatment of solid tumors, including cervical cancer and endometrial cancer. Its mechanism includes blocking PD-1 to enhance antitumor immunity, with ongoing clinical trials in combination with chemotherapy agents for advanced or recurrent cancers[1][2][4][6].

Other names

Recombinant humanized anti-PD-1 monoclonal antibody injectionanti-PD-1 monoclonal antibody BAT1308anti-PD1 monoclonal antibody BAT1308anti-PD 1 monoclonal antibody BAT1308BAT1308 injectionBAT-1308 injectionBAT 1308 injection